Table 4.
Comparison between the 2 groups of the proportion of patients in neutrophil count categories during the study and 1 month after the study
| Montha | Neutrophil count categoryb | Group |
P valuec | |
|---|---|---|---|---|
| Prophylaxis proportion, n (%) | Nonprophylaxis proportion, n (%) | |||
| 1 | 1 | 15 (8.9) | 2 (2.2) | 0.038 |
| 2 | 154 (91.1) | 90 (97.8) | ||
| 2 | 1 | 14 (8.3) | 5 (5.4) | 0.464 |
| 2 | 155 (91.7) | 87 (94.6) | ||
| 3 | 1 | 15 (8.9) | 2 (2.2) | 0.038 |
| 2 | 154 (91.1) | 89 (97.8) | ||
| 4 | 1 | 15 (9.0) | 2 (2.2) | 0.039 |
| 2 | 152 (91.0) | 86 (97.8) | ||
| 5 | 1 | 18 (11.2) | 3 (3.3) | 0.009 |
| 2 | 146 (88.8) | 83 (96.7) | ||
| 6d | 1 | 13 (7.7) | 3 (3.3) | 0.185 |
| 2 | 150 (92.3) | 82 (96.7) | ||
a
Months from start of treatment.
b
Neutrophil count categories (× 109/l): 1: < 2.7; 2: ≥ 2.7.
c
Fisher exact test.
d
One month after stopping treatment.